Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 11 of 114

  1. APHP230813

    Pari Pharma GmbH

    Very preterm neonate (gestational age at birth < 32 WG) with corrected gestational age <45 WG) with indication for sedation in the context of invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  2. APHP230823

    Pari Pharma GmbH

    Adults aged at least 18 years with painful base-of-thumb osteoarthritis

    phase 3 small molecule active

    1 trial

  3. APHP230824

    Pari Pharma GmbH

    Uncomplicated candidemia

    phase 3 small molecule active

    1 trial

  4. APHP230825

    Pari Pharma GmbH

    PEDIATRIC ACUTE MYOCARDITIS

    phase 3 small molecule active

    1 trial

  5. APHP230833

    Pari Pharma GmbH

    Heart failure

    phase 3 small molecule active

    1 trial

  6. APHP230836

    Pari Pharma GmbH

    Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.

    phase 3 small molecule active

    1 trial

  7. APHP230841

    Pari Pharma GmbH

    Population of study participants Pregnant women with PPROM at 22 to 33 weeks’ gestation

    phase 3 small molecule active

    1 trial

  8. APHP230844

    Pari Pharma GmbH

    Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours.

    phase 3 small molecule active

    1 trial

  9. APHP230847

    Pari Pharma GmbH

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  10. APHP230852

    Pari Pharma GmbH

    Patients diagnosed at the study sites with rifampicinresistant tuberculosis during the recruitment period will be evaluated for study inclusion.

    phase 3 small molecule active

    1 trial

  11. APHP230855

    Pari Pharma GmbH

    Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB)

    phase 3 small molecule active

    1 trial

  12. APHP230864

    Pari Pharma GmbH

    Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

    phase 3 small molecule active

    1 trial

  13. APHP230869

    Pari Pharma GmbH

    insomnia, Depressive episode

    phase 3 small molecule active

    1 trial

  14. APHP231089

    Pari Pharma GmbH

    Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is one of the most frequent primary neoplasms of the bone marrow

    phase 3 small molecule active

    1 trial

  15. APHP240792

    Pari Pharma GmbH

    Septic arthritis

    phase 3 small molecule active

    1 trial

  16. APHP240804

    Pari Pharma GmbH

    Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.

    phase 3 small molecule active

    1 trial

  17. APHP240889

    Pari Pharma GmbH

    Aortic bioprothesis implanted patient for valvular heart disease

    phase 3 small molecule active

    1 trial

  18. APHP240909

    Pari Pharma GmbH

    Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment

    phase 3 small molecule active

    1 trial

  19. APHP240920

    Pari Pharma GmbH

    Cutaneous lupus erythematosus

    phase 3 small molecule active

    1 trial

  20. APHP240938

    Pari Pharma GmbH

    Adult patients admitted to the ICU and receiving unplanned invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  21. APHP241011

    Pari Pharma GmbH

    Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  22. APHP241013

    Pari Pharma GmbH

    Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (BCP-ALL) or a B cell lymphoma (BCL)

    phase 3 small molecule active

    1 trial

  23. APHP251262

    Pari Pharma GmbH

    Neisseria gonorrhoeae Infections

    phase 3 small molecule active

    1 trial

  24. APL-2

    Lacuna Pharma Pty Ltd

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  25. APL-2

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    1 trial

  26. APL-2

    Apellis Europe B.V.

    Geographic Atrophy

    phase 3 small molecule completed

    2 trials

  27. APL-2, Pegcetacoplan

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  28. APL2

    Apellis Europe B.V.

    FSGS

    phase 3 small molecule active

    1 trial

  29. APL2-C3G-310

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 3 small molecule active

    1 trial

  30. APR-246 + azacitidine

    Aprea Therapeutics

    MDS

    phase 3 small molecule completed

    1 trial

  31. ARALAST NP 60 mg/kg

    Takeda

    Chronic Obstructive Pulmonary Disease

    phase 3 mab terminated

    1 trial

  32. ARC-10

    Arcus Biosciences

    Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer

    phase 3 small molecule active

    1 trial

  33. ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

    Arcturus Therapeutics Holdings

    COVID-19 Vaccines

    phase 3 mab completed

    1 trial

  34. ARCT-2303

    Arcturus Therapeutics Holdings

    COVID-19

    phase 3 mab completed

    1 trial

  35. ARD-101

    Ark Therapeutics

    Hyperphagia

    phase 3 small molecule on hold

    1 trial

  36. ARG-01-2024

    Laboratoire HRA Pharma

    rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy

    phase 3 small molecule active

    1 trial

  37. ARGX-113

    argenx

    Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  38. ARGX-113

    argenx

    Primary immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  39. ARGX-113-2007

    argenx

    Active Idiopathic Inflammatory Myopathy (IIM)

    phase 3 small molecule active

    1 trial

  40. ARGX-113-2008

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  41. ARGX-113-2009

    argenx

    Bullous Pemphigoid (BP)

    phase 3 small molecule active

    1 trial

  42. ARGX-113-2306

    argenx

    Primary Sjögren’s Disease

    phase 3 small molecule active

    1 trial

  43. ARGX-113-2308

    argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  44. ARGX-113-2309

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  45. ARGX-113-2315

    argenx

    Ocular Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  46. ARGX-113-2402

    argenx

    Primary Immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  47. ARGX-117-2302

    argenx

    Multifocal Motor Neuropathy

    phase 3 small molecule active

    1 trial

  48. ARGX-117-2401

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.